IL1B and in situ carcinoma: CIS-administered rats in this study exhibited inflammation, marked by upregulated NF-κB p65, TNF-α, and IL-1β, decreased IL-10, and the presence of an inflammatory reaction in the alveoli and around small blood vessels.